ritlecitinib + itraconazole

**Ritlecitinib + itraconazole** is a combination of ritlecitinib, an orally active and selective covalent inhibitor of Janus kinase 3 (JAK3) and TEC family tyrosine kinases, and itraconazole, a triazole antifungal agent. Ritlecitinib is approved for the treatment of severe alopecia areata and works by blocking the activity of cytokine signaling pathways involved in autoimmune and inflammatory processes[1][2][3][5]. Itraconazole is an antifungal used primarily to treat a range of fungal infections and inhibits the fungal cytochrome P450 enzyme 14α-demethylase, thereby preventing ergosterol synthesis. This combination may be used for pharmacokinetic interaction studies, as itraconazole is a strong inhibitor of CYP3A4 and is often used to evaluate drug-drug interaction risk for medications metabolized by this enzyme, such as ritlecitinib. There is no indication of a therapeutic combination use for disease treatment with these two agents together; the combination is primarily relevant in clinical pharmacology studies[3].

Brand names

Litfulo (for ritlecitinib; no combination brand name identified)

Other names

PF-06651600 + itraconazole